Metabolic syndrome (MS) is one of the leading risk factors for the development of cardiovascular diseases, type II diabetes mellitus and reproductive system diseases. Currently, not only cardiovascular disease and reproductive history risks related with MS are frequently discussed, but it has been also shown that MS is associated with increased risk of some common cancers (endometrial cancer, postmenopausal breast cancer, colorectal cancer, biliary tract cancers and liver can- 
METABOLIC SYNDROME AND MALIGNANT NEOPLASMS (ETHNIC FACTORS, SEXUAL DIFFERENCE)
Metabolic syndrome (MS) has become a global public health problem due to its high prevalence among the general population. [1] [2] [3] MS is one of the leading risk factors for the development of cardiovascular diseases, diabetes mellitus type II and pathology of the reproductive system, thus leading to severe concomitant diseases and decreased life expectancy in patients.
In 2005, the International Diabetes Federation (IDF) defined common criteria for diagnosing MS. In accordance with IDF guidelines, diagnosis of MS requires the necessary presence of abdominal type of obesity (waist circumference greater than 94 cm for Caucasian men and 80 cm for Caucasian women) combined with at least two of the four additional criteria: increase in blood serum triglyceride level of more than 1.7 mmol/L or previously treated dyslipidemia; decrease in high density lipoproteins (HDL) (less than 1.03 mmol/L for men and 1.29 mmol/L for women); high blood pressure (systolic over 130 mmHg, or diastolic more than 85 mmHg, or antihypertensive therapy in history); increase in fasting blood glucose of more than 5.6 mmol/L or previously diagnosed type II diabetes mellitus. 4, 5 In addition to the main diagnostic criteria, the IDF consensus group recommends to study a number of other parameters associated with MS. Additional metabolic criteria for research are: evaluation of fat distribution disorders (total fat distribution, central fat distribution, adipose tissue biomarkers: leptin, adiponectin, fat content in the liver); atherogenic dyslipidemia (apoprotein B, non-HDL, small particles of low-density lipoproteins), dysglycemia; insulin resistance (insulin fasting level, insulin resistance index, insulin resistance according to the minimal Bergman model); proinflammatory status (elevated level of C-reactive protein and increased levels of inflammatory cytokines -tumor necrosis factor, interleukin-6); prothrombotic status (fibrinolytic factors, tissue activator of plasminogen, etc.) and coagulation factors (fibrinogen, etc.). The study of these factors will eventually modify the diagnostic criteria for MS and also provide additional cliniScal data on different ethnic groups. 4, 6 Not only cardiovascular and reproductive risk factors related to MS are frequently discussed in the literature but it has been also shown that MS is associated with increased risk of common cancers. 3, [7] [8] [9] [10] [11] In a meta-analysis, Esposito et al. 3 showed that MS was associated with certain types of cancer. These associations were more pronounced for women than for men (endometrial cancer, postmenopausal breast cancer, colorectal cancer). For men, statistically significant associations between MS and liver cancer, colorectal cancer and bladder cancer were identified. 2 The relationship between MS and cholelithiasis/biliary tract cancer was found predominantly in Asian populations. 8,9,11
MECHANISMS OF THE INVOLVEMENT OF METABOLIC SYNDROME COMPONENTS IN THE PATHOGENESIS OF MALIGNANT NEOPLASMS
Molecular aspects of MS involvement in carcinogenesis, such as hyperinsulinemia and insulin resistance, hyperglycemia, hyperestrogenemia, hyperleptinemia, and decreased level of blood serum adiponectin have been well studied. All these factors are involved in cell proliferation, apoptosis, angiogenesis, cellular motility, damage to the DNA by active forms of oxygen due to excess glucose ( Figure 1 ). 3, [12] [13] [14] The role of MS in the development of hormone-dependent cancer is still poorly understood. Insulin and insulin-like growth factors (IGFs) under conditions of deficiency of insulin-like growth factor-binding proteins (IGFBPs) are suggested to potentiate the mitogenic effect of estrogens on the endometrium and breast, as well as to modify steroidogenesis due to a direct effect on estrogen synthesis in the ovaries and inhibition of sex steroid-binding globulin production in the liver. 1, 10, 13 The influence of MS on the development of prostate cancer is believed to be caused by multiple effects of insulin (mitogenic effect, inactivation/activation of transcription factors, effect on the synthesis/activity of androgen receptors, activation of aromatase in prostate tissue, activation of ER-alpha receptors). 12, 15 The available literature data suggest that the effect of MS on tumor cells is mediated also through the activation/inactivation of expression of growth and transcription factors, which in complex causes the activation or inhibition of a variety of signaling pathways responsible for proliferation, apoptosis, neoangiogenesis, cell mobility and adhesion, formation of the tumor cell invasive phenotype. 13, 16 In the presence of MS, a complex of hormone-metabolic disorders is formed, including hyperglycemia, hypertriglyceridemia, hypercholesterolemia, hyperinsulinemia, hyperleptinemia, lower serum adiponectin levels and other disorders. Moreover, changes in the serum and tissue levels of leptin and adiponectin and their receptors (Ob-Ra, Ob-Rb, AdipoR1, AdipoR2) in patients with MS are most significant in the relation with expression of transcription and growth factors. 5, [16] [17] [18] [19] [20] [21] F I G U R E 1 Diagram of factors linking the MS with cancer development. 14 Plasma glucose, BMI/waist circumference and triglycerides/FFA affect different complementary processes that can work together to promote cancer development/growth. Additional characteristics of the MS, such as increased HDL and hypertension, are also correlated with cancer growth, but a direct mechanism for these associations has not been confirmed. E = estrone; E 2 = estradiol; A = androgens; mito = mitochondria; ROS = reactive oxygen species; SHBG = sex hormone-binding globulin; FFA = free or nonesterified fatty acids; TG = triglycerides; IGFBPs = insulin-like growth factor-binding proteins [Colour figure can be viewed at wileyonlinelibrary.com]
CHANGES IN THE EXPRESSION OF TRANSCRIPTION AND GROWTH FACTORS IN PERIPHERAL TISSUES AND CANCER TISSUE IN THE PRESENCE OF METABOLIC SYNDROME: THE ROLE OF FAT TISSUE HORMONES LEPTIN AND ADIPONECTIN IN REGULATION OF THE EXPRESSION OF TRANSCRIPTION AND GROWTH FACTORS
Changes in the expression of some transcription and growth factors in various tissues were revealed using the experimental genetic/nongenetic models of MS and animalistic models for studying the imbalance of cellular energy. 13, [22] [23] [24] [25] The revealed spectrum of transcription factors included AMP-activated protein kinase (AMPK), sterol regulatory element-binding protein-1 (SREBP-1), peroxisome proliferator-activated receptors (PPARs), STAT3, NF-kappaB and HIF1 . Adipose tissue is traditionally the source of proinflammatory cytokines (IL-6, TNF ) that can lead to the activation of NF-kappaB and HIF1 in peripheral tissues. 4, 13, 26 The effect of the important adipose tissue hormones, such as adiponectin and adiponectin on the expression of transcription and growth factors in tumors was studied using the cell cultures of colorectal, breast, prostate and endometrial cancers and nontumor cell lines 12, 16, [18] [19] [20] 27 . The spectrum of the revealed transcrip- Adiponectin has been shown to inhibit the proliferation of colon cancer cells through AdipoR1-and AdipoR2-mediated activation of AMPK. 19 Cell lines show that adiponectin inhibits the expression of SREBP-1, which is currently considered to be the most important lipogenic transcription factor involved in the pathogenesis of colorectal and endometrial cancers. 16, 34 23 Activated SREBP-1 increases the expression of lipogenic genes, the most important of which are acetyl CoA carboxylase and fatty acid synthase. The level of SREBP-1 is significantly increased in tissues in animals with obesity and MS. The activation of this factor has been shown to lead to the accumulation of lipids in the liver and kidneys in experimental models of obesity and type II diabetes mellitus. [23] [24] [25] In addition, it has been shown that SREBP-1 is involved in the regulation of glycogen synthesis and the expression of gluconeogenesis genes in the liver of mice. 38 Inhibition of SREBP-1 as a transcription factor leads to a decrease in the expression of many genes involved in the biosynthesis of cholesterol, fatty acids, triglycerides, bioactive lipids, which is associated with the suppression of proliferation and invasiveness of androgen receptor-expressing prostate and breast tumors. 3, [39] [40] [41] Leptin also activates the transcription factor STAT3 mainly through its cellular OB-Rb receptor leading to apoptosis disruption that is typical for different cancer cell lines (breast, colon and poorly differentiated ovarian carcinomas). 42, 43 
TA B L E 1 Molecular targets for therapy of malignant tumors associated with metabolic syndrome

Targets
The expected effect on the target in terms of impact on tumor growth and metastasis
Drugs and active substances affecting the target
References
Leptin and OB-Rb
The reduction of the level of leptin to blood and biological fluids with a decrease in the leptin-dependent activation of signaling cascades involved in proliferation, inhibition of apoptosis, the formation of a chemoresistant phenotype of tumor cells with the appearance of clones of stem tumor and non-tumorous cells of the microenvironment, excessive cellular mobility leads to a pronounced antitumor effect.
Circicum, silibinin, combinations of circumcumin-silibinin, metformin, nonpharmacological approaches to weight loss 13, 43, 50 Adiponectin,
AdipoR1, AdipoR2
The effect is opposite to leptin, for most tumors adiponectin is considered as a protein with antiangiogenic, antiproliferative activity, activating a number of intracellular cascades involved in inducing apoptosis of the cell. PPAR-agonists induce adiponectin release from adipose tissue to the blood. The involvement of AdipoR1 in protein complexes and cascades associated with the stimulation of the proliferation of ER -positive breast tumors dictate the need for a detailed study of the effect of adiponectin in different types of tumors.
Synthetic low-molecular substance similar to adiponectin -AdipoRon, PPAR-agonists, non-pharmacological approaches to weight loss 19 
SREBP-1 and its regulators
Inhibition of SREBP-1 as a transcription factor leads to a decrease in the expression of many genes involved in the biosynthesis of cholesterol, fatty acids, triglycerides, bioactive lipids, which is associated with the suppression of proliferation and invasiveness of AR-positive prostate tumors, breast tumors 
MOLECULAR TARGETS FOR THERAPY OF MALIGNANT NEOPLASMS ASSOCIATED WITH METABOLIC SYNDROME
The most promising molecular targets for therapy of malignant tumors associated with MS are shown in Table 1 The use of these drugs in patients with breast, prostate and colorectal cancer with MS is quite encouraging. 13, 49 A summary of the effects of drugs on molecular targets for the therapy of malignant tumors associated with the MS is shown in Figure 2 .
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